Through the improvement of systemic therapy with, e.g., immunotherapy targeting Programmed cell death protein 1 (PD‐1) or Programmed death-ligand 1 (PD‐L1), the survival of patients is steadily improving even in advanced cancer stages [13]. The gene discussed is PDCD1; the disease is cancer.